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E-mail address: jsloane@bidmc.harvard.edu (J.A. SMultiple sclerosis is a common demyelinating disease that worsens over the course of disease, a sig-
niﬁcant problem in clinical management. Disability in MS is signiﬁcantly promoted by poor repair
and remyelination of lesions. Both oligodendrocyte recruitment and maturation defects are seen
as major causes of poor remyelination in MS. The mechanisms behind impaired remyelination in
animal models include involvement of the Notch1, wnt, and hyaluronan/TLR2 pathways. RXR/PPAR
signaling has also more recently been identiﬁed as an important regulator of remyelination. The
local inﬂammatory milieu also appears to play critical and conﬂicting roles in promotion and inhi-
bition of remyelination in MS. Understanding the forces regulating remyelination in MS represents
an exciting and important initial step towards developing therapeutics targeting chronic disability
in MS.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
Demyelination is the pathological removal of myelin sheaths
that surround axons and enhance axonal function. Multiple sclero-
sis is characterized by repeated focal demyelination of the brain,
which accounts for a large degree of disability associated with this
disease. Demyelinated lesions are often poorly repaired and this
likely worsens the duration and chronicity of disability in the short
term. The extent and prevalence of disability also increases in most
patients with longstanding MS.
Two components of MS pathology are central to disability in
MS: axonal injury and impaired remyelination within lesions.
Remyelination is the process of creating newmyelin sheaths on ax-
ons that have been demyelinated. Remyelination restores axonalcal Societies. Published by Elsevier
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loane).function by enhancing saltitory conduction and axonal conduction
velocity. Remyelination may also restore trophic support to axons
and prevent further axonal damage and loss.
Animal models often show robust remyelination is attainable
but remyelination appears to be limited in MS. In this article, we
review what is known about remyelination in MS and describe po-
tential mechanisms behind why remyelination fails in this disease.
Lastly, we discuss the interplay between the local inﬂammatory
milieu and remyelination in MS.
2. Does remyelination occur in MS?
Many studies have demonstrated that remyelination can occur
within MS lesions [1–7]. In 1965, investigators ﬁrst documented
incomplete remyelination within the margins of MS lesions [5].
Later, the term ‘‘shadow plaque’’ was coined to deﬁne homoge-
nously remyelinated lesions observed in MS [8,9]. Shadow plaques
are now commonly identiﬁed in MS, characterized by their well-
demarcated borders and incomplete myelination compared to nor-
mal white matter. However, a large number of lesions exhibit no
remyelination. Furthermore, extensive remyelination is observed
only rarely [1–4,7], indicating remyelination is insufﬁcient in most
MS lesions.
In rather dichotomous fashion, remyelination occurs in some
MS patients and not in others. In some MS patients, remyelination
occurs in most lesions and up to 96% total lesion area. In others,B.V. Open access under CC BY-NC-ND license.
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largely absent [3,10]. Thus, remyelination is possible in some cases
of MS and is blocked in a signiﬁcant proportion of others.
Based on study ofMS pathology, possible explanations for differ-
ences in remyelination potential include disease heterogeneity or
differences indisease chronicity. Lucchinetti et al. identiﬁed fourdif-
ferent subtypes of MS lesions that occurred in mutually exclusive
fashion [11]. In type III and IV lesions, oligodendrocytes were rela-
tively depleted and no shadow plaques were observed. In contrast,
inﬂammation was more prominent in type I and II lesions and was
associatedwith less oligodendrocytedestruction.A clear association
between oligodendrocyte loss and lack of shadow plaques was ob-
served, but more work is needed to strengthen the correlation.
However, it is clear that differences in remyelination potential
are seen when comparing MS cases early and late in the course
of disease. More remyelination in early stages of MS is observed
by many groups [1,5,6], although not all reports agree [3]. Remye-
lination may even begin within a month or two after active demy-
elination [6]. In contrast, remyelination in late stage MS appears
sparse and restricted to borders of inactive lesions [1,3,5].
Remyelinated areas frequently contained lipid-laden macro-
phages or microglia, which are in contact with thinly remyelinated
ﬁbers [6,9], suggestive of active cycling between demyelination
and remyelination. In addition, recurrent demyelination within
shadow plaques has been documented, and recurrent bouts of
demyelination could lead to permanent demyelination [4,12].
Oligodendrocytes potentially can survive a bout of demyelina-
tion and may contribute to subsequent remyelination attempts
[4,6,13–15]. However, oligodendrocyte depletion over time after
repeated bouts of demyelination may make remyelination impos-
sible. Consistent with this hypothesis, MS lesion cores late in the
course of disease often contain only a few OPCs [13,14,16–18]
but exhibit remyelination at the lesion edge, suggesting forces reg-
ulating remyelination are insufﬁcient to reach the lesion core.
Thus, at least in late stage MS, failure of oligodendrocyte recruit-
ment is a signiﬁcant reason for poor remyelination of lesions. It
is less clear what prevents remyelination in early MS lesions, but
could relate to characteristics of local inﬂammatory processes or
intrinsic dysfunction of oligodendrocytes.
3. Does oligodendrocyte dysfunction prevent remyelination
in MS?
For remyelination to occur, oligodendrocyte progenitor cells
(OPCs) must survive, proliferate, and migrate to lesions. Once with-
in MS lesions, OPCs must differentiate to pre-oligodendrocytes,
premyelinating oligodendrocytes, and then mature myelinating
oligodendrocytes to then regenerate myelin sheaths. In theory,
remyelination can be blocked at any point in the remyelination
process: oligodendrocyte survival, proliferation, migration, matu-
ration, and/or myelin sheath formation. In late stage MS, remyeli-
nation appears limited by oligodendrocyte density, which could be
a product of impaired survival, proliferation, and/or migration of
oligodendrocytes.
Alteration in oligodendrocyte maturation can be studied in MS
by measuring densities of OPCs, pre-oligodendrocytes, premyeli-
nating oligodendrocytes, and mature myelinating oligodendro-
cytes within the MS brain. While low oligodendrocyte densities
can be observed in early MS lesions, multiple studies clearly indi-
cate that numerous OPCs and premyelinating oligodendrocytes
are commonly found within MS lesions. Oligodendrocyte progeni-
tor cells are numerous within MS lesions, at about half the density
of normal appearing white matter [18,19]. In fact, periplaque white
matter and shadow plaques showed a higher density of Olig2+ cells
compared to controls. O4+ GalC- pre-oligodendrocytes are also
plentiful in most lesions in chronic MS [17].Interestingly, there was a signiﬁcant positive correlation be-
tween the densities of pre-oligodendrocytes and macrophages in
MS cord lesions [15,20], although this is controversial [14]. This
ﬁnding suggests a possible beneﬁt of chronic inﬂammation to
maintaining elevated oligodendrocyte densities within MS lesions.
Alternatively, this ﬁnding could reﬂect the notion that more recent
lesions contain more oligodendrocytes and that oligodendrocyte
density lessens as lesions age.
Oligodendrocyte differentiation in MS lesions appears to be
blocked late in the oligodendrocyte lineage since very few GalC+
mature oligodendrocytes were found within MS lesions [17]. These
cells were rounded and possessed few cellular processes consistent
with an immature or aberrant state [17,20]. The density of PLP+
premyelinating oligodendrocytes is also signiﬁcantly reduced in
MS lesions compared to normal appearing white matter [21]. In
about 7% of all MS lesions, the density of premyelinating oligoden-
drocytes approximated the density found in the developing brain.
As mentioned above, the regional distribution of oligodendro-
cytes within the MS lesion and its margins has been studied as
well. While all demyelinated lesions often have reduced oligoden-
drocyte densities roughly 0-50% that of normal white matter,
remyelinated regions have oligodendrocyte densities approaching
or exceeding normal white matter [7,13,14]. This can vary when
examining MS lesions early and late in the course of disease. Inter-
estingly, some investigators have observed signiﬁcantly increased
oligodendrocyte densities at the lesion edge, although this has
never been adequately quantiﬁed [1–4]. Oligodendrocytes within
lesion edges or in remyelinating areas do not appear to be in a pro-
liferative state [17,18,22]. Thus, given an abnormal low density of
oligodendrocytes within lesion cores, the increase in oligodendro-
cyte density within lesion margins may indicate migration to le-
sion cores is impaired. This may be especially true for late stage
MS lesions that show remyelination restricted to margins, a possi-
bility our group is actively investigating.
Beyond the oligodendrocyte recruitment and maturation, mye-
lination also requires contact between axons and oligodendrocytes
and creation of multiple wraps of oligodendrocyte processes
around the axon, culminating in the myelin sheath. Clearly, oligo-
dendrocytes present in MS lesions express PLP, and variants of MBP
[21,23], which are important myelin sheath proteins. Thus, these
premyelinating oligodendrocytes contact axons and appear primed
to myelinate the sheath. This suggests a block in further matura-
tion beyond the premyelinating state, or in the ability of the oligo-
dendrocyte to myelinate the axon. Axons may also lose receptivity
to myelination in MS lesions [24].
Overall, there are a number of possible issues that limit remye-
lination within MS lesions. These include most prominently prob-
lems with oligodendrocyte maturation and the formation of
myelin sheaths. Other signiﬁcant factors include impaired oligo-
dendrocyte migration and/or proliferation in lesions. Several labs
have begun working of deciphering the molecular pathology that
limits remyelination in hopes of some day enhancing remyelina-
tion in MS patients. Initial data indicate a number of possible cul-
prit molecular pathways or signals play a role in blocking
remyelination, including Notch1 signaling, wnt/ß-catenin, hyalu-
ronan, LINGO1, and RXR among others.
4. Is remyelination normal?
Although remyelination does occur in MS, myelin sheaths
formed in remyelination are structurally abnormal [1,5,9,10]. In
the ﬁrst observations of MS lesions by EM, thinly myelinated axons
were observed within chronic MS lesions [5]. Further studies found
thinly myelinated ﬁbers primarily at the margins of chronic lesions
[1]. The internodal length of these remyelinating sheaths was also
found to be shorter than normal [1,6]. Nodal length also is widened
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nated axons show altered saltitory conduction and reduced con-
duction velocity compared to normal myelinated axons, which
can often be observed in MS patients by physical exam or evoked
potentials.
In spite of abnormal myelin sheath measurements, all remyeli-
nating internodes within MS lesions appear to have normal paran-
odal architecture [1,9]. In addition, short myelin sheaths within
shadow plaques show proper localization of paranodal Caspr, no-
dal Nav channels, and juxtaparanodal Kv channels, while demyeli-
nated axons had more diffuse localization of these proteins [25,26].
Furthermore, the length of Caspr, Kv channel, and nodal sodium
channel aggregates in shadow plaques is identical to normal MS
white matter. In addition, Nfasc186 and MOG appeared to localize
appropriately in myelin sheath domains in shadow plaques [27].
Only Nfasc155 showed slightly diffuse paranodal mislocalization
in remyelinating areas [27], suggesting Nfasc155 localization to
paranodes is a late event in remyelination.
Whether abnormal myelin sheath ultrastructure represents a
problem speciﬁc to myelination itself or a more general problem
with oligodendrocyte function is unclear at present. For example,
the cultured oligodendrocyte generates multiple branching pro-
cesses in culture that can be short/long and branched/unbranched
depending on various conditions. A short oligodendrocyte process
would likely result in a thin myelin sheath since the process would
be unable to wrap as many times as a longer process. This is con-
sistent with ﬁndings of oligodendrocyte process number and num-
ber of associated internodes in MS lesions [21]. Nevertheless, it is
equally possible regulatory signals and sheath components that
regulate the formation of the very specialized sheath structure
could restrict the sheath thickness and lengths of internodes and
nodes in MS lesions. This is a poorly understood but important as-
pect of myelin biology that should develop more rapidly with bet-
ter scientiﬁc tools.5. What pathways regulate remyelination?
5.1. Notch1 pathway
Expressed by oligodendrocytes, Notch1 receptor is a well-
known regulator of OPC maturation [28–30]. Notch1 responds to
membrane-bound ligands, Jagged1 and Delta, and inhibits OPC
maturation [28,31]. Since Jagged1 can be expressed by axons, neu-
rons, and astrocytes throughout the brain [32], increases in Jag-
ged1 may stimulate Notch1 on oligodendrocytes and block
remyelination in MS.
John et al. found that TGF-ß1, an upregulated cytokine in MS,
induced expression of Jagged1 in reactive astrocytes [31]. Jagged1
was also expressed by reactive astrocytes in demyelinated but not
remyelinated MS lesions. The borders of acute MS lesion borders
demonstrated staining for Jagged1 as well as Notch1 and the inhib-
itory basic helix-loop-helix protein, Hes5, suggesting the presence
of active Jagged1/Notch1 signaling.
However, initial animal models examining Notch1 function in
remyelination contradicted in vitro blockade of OPC maturation
by Notch1 signaling. First, alterations in Jagged1 and Notch1
expression in animal models did not match what was found for
MS lesions. Lesioning of the trigeminal tract by ethidium bromide
increased rather than decreased Jagged1 expression within remye-
linating lesions [32]. Similarly in EAE, with remyelination, Notch1
expression on oligodendrocytes was only observed in remyelinat-
ing lesions [33]. Secondly, conditional deletion of Notch1 in PLP+
oligodendrocytes had no effect on remyelination after cuprizone
mediated demyelination, based on G ratio and percent remyelina-
tion [32]. Oligodendrocyte recruitment within lesions was alsounaffected. Thus, these ﬁndings did not support a signiﬁcant role
of Notch1 in remyelination in animal models.
However, PLP+ oligodendrocytes may be too far along in matu-
ration to respond to Jagged1/Notch1 signaling in the above in vivo
experiments. In support of this possibility, experiments using CNP-
cre mice instead showed conditional deletion of Notch1 in CNP+
oligodendrocytes promoted precocious oligodendrocyte matura-
tion [34]. In addition, using Olig2-driven cre mice, Zhang et al.
showed that conditional deletion of Notch1 promoted an earlier
pattern of oligodendrocyte maturation in development [34]. After
lysolecithin injection, remyelination was more extensive in condi-
tional Notch1 deleted mice. More remyelinated sheaths were ob-
served in these mice as well. In addition, in vitro myelination
experiments utilizing OPCs and DRGs found that Notch1 siRNA en-
hanced myelination [34]. Therefore, Notch1 signaling may block
oligodendrocyte maturation in earlier stages differentiation.
Recently, activation of Notch1, characterized by cleavage and
generation of an intracellular fragment (NICD), was observed with-
in oligodendrocytes within MS lesions [29]. Nuclear translocation
of NICD is required for complete Notch1 signaling. However, NICD
forms aggregates outside nucleus and its nuclear translocation
does not occur, suggesting that Notch1 signaling was not com-
pletely activated.
This ﬁnding argued that canonical Notch1 signaling, via ligand
delta, Jagged1, or Lag2 [35], was not operative in MS. In contrast,
contactin, a non-canonical Notch1 ligand [30], was upregulated
in MS lesions [29]. Contactin/Notch1 stimulation actually induced
MAG upregulation in vitro while Jagged1 stimulation had no effect,
in contrast to previous ﬁndings [31]. Because contactin is normally
expressed at the axonal paranode, unmyelinated axons receptive
to myelination may upregulate contactin to signal oligodendro-
cytes to mature and begin myelination.
The blockade in NICD nuclear translocation is dependent on
expression of TIP30, an inhibitor of Importin ß [29]. Both Lamin
B1 and TIP30 were increased in MS lesions. In remyelinated sha-
dow plaques, TIP30-cells with nuclear NICD+ increased in shadow
plaques compared to chronic inactive lesions. However, more
TIP30+ cytoplasmic NICD+ cells were observed in chronic inactive
plaques, suggesting TIP30 blocked remyelination in these lesions.
Consistent with this hypothesis, expression of TIP30 blocked cont-
actin dependent expression of MAG and cellular differentiation
in vitro. In addition, TIP30 blocked nuclear translocation of NICD.
Overall, the role of Notch1 in remyelination in MS is becoming
more, not less, complicated over time. In animal models of MS,
Notch1 appears to block remyelination, although it is unproven
whether Jagged1 is the responsible Notch1 ligand [34]. Studies uti-
lizing MS tissue show that Notch1 signaling is blocked by TIP30
upregulation [29]. Because Notch1 signaling is interrupted within
chronic lesions lacking remyelination, Notch1 signaling appears
to promote remyelination. While in vitro experiments support this
claim, animal experiments still are needed to fully prove the bidi-
rectional function of Notch1 in remyelination.
5.2. LINGO1 pathway
Leucine rich repeat and Ig domain containing 1 (or LINGO1) was
ﬁrst shown to be expressed exclusively in brain [36], and speciﬁ-
cally by neurons and oligodendrocytes in normal brain and acti-
vated microglia and astrocytes in MS [36–39]. In CNS
development, LINGO1 expression is regulated by NGF/TrkA signal-
ing [40].
Since LINGO1 expression was found to increase in spinal cord
injury [36], LINGO1 was originally tested for effects on CNS repair.
Myelin debris inhibits neurite outgrowth and dominant-negative
LINGO1 blocks these effects [36]. LINGO1 appears to act through
at least NgR1 since LINGO1 binds strongly to cells expressing
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binding. Pulldown experiments also show that LINGO1 directly
interacts with both p75 and NgR1 and overexpression of each
receptor enhances LINGO1 effects in vitro.
Not only does LINGO1 appear to have a repressive role in neu-
rite outgrowth, but LINGO1 also restricts oligodendrocyte matura-
tion and myelination as well [37,38,40]. LINGO1 blocks
oligodendrocyte differentiation, MAG and MBP expression, and
myelin formation in vitro in a dose dependent manner [37,40]. In
contrast, siRNA directed at LINGO1 enhances oligodendrocyte pro-
cess length and myelin sheet formation [37]. Repression of LINGO1
function by blocking antibodies or dominant negative-LINGO1
transfection enhances myelin sheet formation, induction of MBP
expression, and myelination in vitro [37,38,41]. These effects are
speciﬁc to CNS myelination as LINGO1 has no effects on Schwann
cell myelination in vitro [40]. The repressive effect of LINGO1 ap-
pears to work through RhoA activation. LINGO1 antagonists block
RhoA activation in oligodendrocytes in vitro [37]. Dominant nega-
tive LINGO1 also enhances fyn phosphorylation [37], which regu-
lates RhoA function [42].
In vivo expression of LINGO1 also affects myelination as
transgenic mice expressing axonal LINGO1 show reduced cord
myelination [40]. Conversely, LINGO1 KO mice show increased
myelination in development and oligodendrocyte cultures contain
an increased percentage of mature oligodendrocytes [37]. Because
neurons and oligodendrocytes cooperate in the formation of
myelin in vivo, it is unclear what cell(s) are responsible for effects
of LINGO1 on myelination. However, LINGO1 most likely regulates
oligodendrocyte function based on in vitro studies utilizing
puriﬁed oligodendrocytes.
Inhibition of LINGO1 function enhances remyelination in sev-
eral models of de/remyelination. EAE in LINGO1 null mice was less
severe, probably due to non-hematologic effects as T cell responses
were no different between genotypes in terms of cytokine produc-
tion [38]. In contrast, more remyelination was seen in LINGO1 null
mice, and possibly accounted for lower clinical EAE scores. It is
important to note that peak EAE scores were also signiﬁcantly low-
er in LINGO1 null mice, indicating that loss of LINGO1 expression
lessens the severity of active EAE as well as improving remyelina-
tion in chronic stages. In keeping with this broad effect of LINGO1,
anti-LINGO1 antibodies blocked severity of EAE at all stages of dis-
ease [38]. Histological evidence of remyelination and fractional
anisotropy, an MRI measure of myelin content, was increased with
LINGO1 antibody treatment. LINGO1 antibody treatment started
after onset of EAE was also beneﬁcial, suggesting LINGO1 can neg-
atively impact chronic EAE in isolation from acute.
This work with LINGO1was extended to other de/remyelination
models. LINGO1 blocking antibodies enhanced remyelination of
cerebellar slice cultures after chemical demyelination [41]. Cocul-
tures of oligodendrocytes and dorsal root ganglion cells produced
more myelinated segments after LINGO1 antibody treatment as
well. LINGO1 blocking antibodies also accelerated myelination of
neonatal cerebellar slices in vitro. Remyelination after lysophos-
phatidylcholine injection to the dorsal columns is enhanced by
LINGO1 blocking antibody. Both ultrastructural evidence of remye-
lination as well as motor evoked potentials support remyelination
was enhanced by LINGO1 blocking antibodies. In the cuprizone
model, LINGO1 blocking antibodies enhanced remyelination as
well as increased mature CC1+ oligodendrocyte numbers. Thus,
many reports provide substantial support for the hypothesis that
LINGO1 expression in MS blocks remyelination.
5.3. Hyaluronan pathway
While other glycosaminoglycans accumulate at lesion borders,
hyaluronan (HA) appears to accumulate within lesion cores[43–45]. Elevations in hyaluronan are also seen in EAE lesions
[45]. At peak EAE (14 days post inoculation), HA molecular weight
broadly ranged from 6150 to 1000 kDa in size. This changed to pri-
marily 1000 kDa in size at 30 dpi. T cells and microglia produce
200–400 kDa whereas astrocytes produce 900–1000 kDa HA. To
test the hypothesis that HA blocks remyelination in MS lesions,
HA was coinjected with a demyelinating agent, lysolecithin. While
high molecular weight (HMW) HA (900 kDa) blocked remyelina-
tion based on MBP staining, LMW HA (300 kDa) had no effect.
Neighboring oligodendrocytes were identiﬁed as pre-oligodendro-
cytes with no staining for mature oligodendrocytes. Cultured oligo-
dendrocytes also did not mature to MBP+ oligodendrocytes in the
presence of HMW HA. In this paper only, LMW HA had no effect
as well on maturation state.
Our group hypothesized that hyaluronan could stimulate Toll-
like receptors, TLR2 and TLR4, which are known HA receptors
[46–49]. In addition, TLRs block the differentiation of a variety of
cell types [50]. We found that oligodendrocytes strongly expressed
TLR2 [50], whereas astrocytes and microglia expressed multiple
TLRs including TLR2 and TLR4 [51–54]. Known agonists of TLR2
but not of TLR4 blocked oligodendrocyte maturation, indicating
some TLR2 speciﬁcity to oligodendrocyte maturation. In dose
dependent manner, hyaluronan also blocked oligodendrocyte mat-
uration in vitro. Neutralizing antibodies to TLR2 but not TLR4 or
CD44, another hyaluronan receptor, blocked effects of hyaluronan
on oligodendrocyte maturation. We repeated lysolecithin induced
demyelination experiments with coinjections of hyaluronan and
found that TLR2 null mice exhibited more rapid and efﬁcient
remyelination in vivo.
Because LMW HA but not HMW HA stimulates TLR2 and TLR4
[46–49], we hypothesized that HMW HA may be processed by
hyaluronidases to smaller hyaluronan fragments that then
stimulate TLR2. Hyaluronidases are expressed by oligodendro-
cytes and hyaluronidase activity was required for blockade of oli-
godendrocyte maturation by HMW HA [50], although other
groups initially found otherwise [45]. Thus, remyelination block-
ade in MS may require hyaluronan synthesis, partial hyaluronan
degradation, and stimulation of TLR2 on oligodendrocytes. Many
of these steps remain to be tested, and we are currently pursuing
these goals.
5.4. Wnt/ß-catenin pathway
Another novel pathway involved in both myelination and
remyelination is the canonical wnt signaling pathway [55–57].
The wnt/ß-catenin pathway is an important negative regulator of
dorsal oligodendrocyte maturation in development [55]. Treat-
ment of cord explants or primary mixed glial cultures with wnt
conditioned media suppresses O4+ oligodendrocyte development.
In addition, pharmacological inhibition of GSK3ß, which is down-
stream of wnt signaling, blocked O4+ oligodendrocyte develop-
ment without effects on OPC numbers.
The role of the wnt pathway in remyelination was uncovered by
screening 1040 in situs of transcription factors in a mouse lysolec-
ithin injection model at 5, 10 and 14 days post lesion [56]. From
this initial screening, Fancy et al. found altered gene expression
in positive and negative regulators of the wnt pathway. Three mur-
ine multiple sclerosis models were used to conﬁrm wnt’s role in
remyelination: lysolecithin cord injections, cuprizone intoxication,
and ethidium bromide injection into the cerebellar peduncles. In
the lysolecithin model, TCF4, a major transcription factor involved
in wnt signaling, is co-expressed in Olig2-postive cells in lesioned
adult spinal cord, but not the unlesioned adult spinal cord. TCF4
was expressed by oligodendrocyte progenitor cells, but was not ob-
served in cells containing cytoplasmic Olig1 and PLP, both markers
of the mature oligodendrocyte. Conﬁrming relevance of TCF4 to
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mouse expressing dominant negative TCF4 exhibited normal OPC
development but grossly impaired oligodendrocyte maturation
[57].
Mice expressing a ß-catenin-TCF4- ß-galactosidase reporter
were then used to demonstrate wnt pathway activity during devel-
opment and remyelination in the adult after injury [56]. In these re-
porter mice they found galactosidase activity in Olig2+ cells in the
spinal cord onpostnatal day 1 and in portions of the corpus callosum
on postnatal day 5. In adult spinal cord, only following lysolecithin
injection, was there signiﬁcant upregulation of ß-galactosidase
activity. Thus, the wnt pathway is likely involved in developmental
myelination as well as adult remyelination after injury.
Next, the authors generated mice expressing dominant active b-
catenin in Olig2+ cells to determine whether ß-catenin could sup-
press developmental myelination [56]. At postnatal days 9 (p9) and
15 (p15), these mice had signiﬁcantly reduced PLP+ oligodendro-
cytes in spite of normal Olig2+ densities. These mice also exhibited
signiﬁcant ataxia, tremor as well as hypomyelination at p15 but
not in adults, indicating a delay rather than a block in developmen-
tal myelination. In contrast, when ß-catenin was conditionally
knocked out of Olig1+ cells, precocious oligodendrocyte develop-
ment in spinal cord was observed during embryogenesis [57].
It remains to be seen whether the wnt pathway is involved in
remyelination in MS. Wnt pathway and protein expression was ob-
served in active MS lesions but not in chronic lesions or normal
adult white matter [56]. As yet, it is unclear whether remyelination
is inhibited in areas where wnt signaling is present.
Histone deacetylasese (HDACs) have also recently been identi-
ﬁed as key regulators of oligodendrocyte maturation in develop-
ment and remyelination [57–59]. Since HDAC1 negatively
regulates wnt and notch signaling in the retina [60] and is required
for oligodendrocyte lineage speciﬁcation [61], there may be a con-
nection between HDACs, wnt and/or notch signaling, and oligoden-
drocyte maturation and remyelination. To study whether
speciﬁcallyHDAC1/2 regulate oligodendrocyte lineage fates and oli-
godendrocyte maturation in development, Huang et al. generated
HDAC 1/2 double cKO mice mediated by Olig1-Cre [57]. No oligo-
dendrocytes or OPCs were observed in double cKO mice. In culture
experiments, oligodendrocytes were observed but oligodendrocyte
maturationwas completely blockedwithout affectingmotorneuron
or astrocyte numbers. Although HDACs can regulate wnt and notch
signaling [60], elevations in only ß-catenin activity were seen in
double cKO HDAC1/2 mice [57] indicating that HDAC1/2 regulate
wnt signaling but have no effect on notch signaling.
5.5. RXR pathway
Using a microarray discovery approach, retinoid X receptor
gamma (RXRc) expression was shown to be signiﬁcantly upregu-
lated in focal demyelination of rat cerebellar peduncle at 14 and
28 days post lesion (dpl), compared with 5 days [62]. The expres-
sion of RXRc increased signiﬁcantly from 5 through 28 dpl in both
Olig2+ cells and CC1+ cells, indicating that oligodendrocytes were
important RXRc expressing cells. Furthermore, RXRc had differen-
tial subcellular localization depending on oligodendrocyte matura-
tional state, as RXRc was found cytosol of Nkx2.2+ OPCs and in the
nuclei of CC1+ mature oligodendrocytes. Because of this differential
subcellular localization, sequestering RXRc in cytosol may inhibit
oligodendrocyte differentiation. Likewise, stimulation and nuclear
localization of RXRc leads to oligodendrocyte maturation in vitro.
Consistent with a role for RXRc in promoting oligodendrocyte mat-
uration, in vitro transfection of RXRc siRNA promoted a signiﬁcant
decrease in MBP expression. In addition, RXR antagonists blocked
oligodendrocyte maturation and myelination in vitro.In MS lesions, subcellular localization of RXRc correlated with
remyelination status. More nuclear RXRc localization was
observed in remyelinating lesions compared to chronic inactive le-
sions. In addition, nuclear RXRc was seen in active lesions and
periplaque white matter compared to normal control white matter,
supporting RXRc activation even in relatively unaffected areas of
the MS brain. In vivo conﬁrmation of RXR function in remyelina-
tion was shown when treatment with 9-cis retinoic acid improved
remyelination after toxin-induced demyelination of the cerebellar
peduncles. Furthermore, a transient decrease in CC1+ mature oligo-
dendrocytes was also observed in RXRc knockout mice after lyso-
lecithin induced demyelination, suggesting of transient delay in
oligodendrocyte maturation during lesional remyelination and
repair.
RXR signaling occurs via three pathways: homodimerization, li-
gand-associated (permissive) heterodimerization, and non-permis-
sive heterodimerization. Since 9-cis retinoic acid enhanced
remyelination in vivo [62], RXRc likely functions through heterodi-
merization with other nuclear receptors, including other retinoic
acid receptors, liver X receptors, peroxisome proliferator activator
receptors (PPAR), vitamin D receptors, thyroid hormone receptors,
as well as nuclear receptors, Nr2f1 and Nr4a2, most of which have
known roles in MS or MS animal models [62–65].
5.6. Other factors
There are a number of relatively new factors that may inﬂuence
remyelination in MS. NG2, a chondroitin proteoglycan expressed
by oligodendrocytes, is upregulated in lysolecithin lesions in the
spinal cord [66]. A substrate coated with NG2 blocks OPCs matura-
tion to O1+ status but not OPC process outgrowth. As NG2 is par-
tially degraded by MMP9, pretreatment by MMP9 reduced effects
of NG2 on OPC maturation in vitro [66]. Although NG2 appears
to inhibit OPC maturation, it is unclear whether NG2 blocks remye-
lination at present.
Myelin transcription factor (Myt1) is a zinc-ﬁnger transcription
factor that regulates PLP transcription [67]. Myt1 localizes to nuclei
of immature oligodendrocyte progenitors and its expression is
downregulated in mature oligodendrocytes [67–69]. Dominant
negative Myt1 blocks OPC maturation and slightly inhibits prolifer-
ation, indicating Myt1 is primarily required for OPC maturation
[69]. When Myt1 was examined in MS tissue, Myt1 localized to nu-
clei of presumed oligodendrocytes in periplaque white matter and
cores of acute and chronic plaques [69]. More Myt1+ cells were ob-
served in periplaque white matter than in normal appearing white
matter. In a murine hepatitis virus infection animal model of
demyelination/remyelination, Myt1 localized to nuclei of OPCs in
lesions and increases in Myt1+ OPC density correlated with remye-
lination timing [69]. At least in Xenopus, Myt1 functions in cooper-
ation with bHLH transcription factor X-NGNR-1 and is negatively
regulated by the Notch/Delta signal transduction pathway [70].
Thus, Myt1 may be intimately associated with the function of
Olig1/2 and/or Notch1 in terms of OPC maturation.
6. The role of innate immunity in remyelination
Inﬂammation has an important and poorly understood role in
remyelination in MS. Clearly, the primary mechanism of demyelin-
ation in MS is via immune related pathways. A number of beneﬁ-
cial treatments for MS are based on modulation or inhibition of
immune mechanisms. However, non-immune processes could
dominate the chronic later phases of MS. This hypothesis is sup-
ported by the relative paucity of inﬁltrating leukocytes late in dis-
ease and that current MS treatments appear to have little impact
on progression.
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inﬂammatory cytokines in remyelination. Deletion of pro-inﬂam-
matory cytokines, including IL1ß and TNFa result in impaired
remyelination indicating that components of the inﬂammatory
cascade in MS may create a beneﬁcial environment for remyelina-
tion [71–75]. As discussed above, inﬂammatory inﬁltrates are often
associated with increased remyelination and a reduction in inﬂam-
mation seen in chronic MSmay reduce remyelination potential late
in disease. Thus, inﬂammatory processes may also enhance remye-
lination and repair of MS lesions.
Many of the pathways tied to remyelination have additional
roles in modulating inﬂammatory processes in MS and animal
models. Most prominently, Toll-like receptors, including TLR2,
have a prominent role in EAE induction as well as chronic phases
of EAE. Initial work found that TLR4 and TLR9 expression is essen-
tial to EAE induction while TLR2 expression has no role in EAE [76].
However, further work by our group and others found that TLR2
expression worsened chronic phases of EAE [77] (data not shown).
While TLR2 was hypothesized to maintain chronic inﬂammation in
EAE by one group [77], we hypothesize that TLR2 may directly
block oligodendrocyte maturation and remyelination indepen-
dently of inﬂammatory stimulation [50]. We are currently working
on resolving this particular controversy.
RXRs and PPARs, well known for their role in MS, likely play a
cooperative role in regulating inﬂammation and remyelination. In
fact, PPAR activity requires heterodimerization of RXRs and PPARs
[78,79]. Stimulation by either PPAR and RXR agonist blocks inﬂam-
matory activation of microglia in vitro [80,81]. However, PPARc
stimulation with 15d-PGJ(2) acts cooperatively with 9-cis retinoic
acid, an RXR agonist, to inhibit microglial activation, suggesting
PPARc/RXRc heterodimerization occurs within microglia blocking
inﬂammatory activation [81]. Although not proven, RXRcmay also
heterodimerize with PPARs in oligodendrocytes to permit remyeli-
nation as suggested by Huang et al. [62].
Because RXRs are required for PPAR function, RXRs may be re-
quired for the many known effects of PPARs in MS. First, the PPAR
agonist, 15d-PGJ(2), improved clinical incomes in EAE and de-
creased macrophage and CD4+ T cells inﬁltrating spinal cord in
EAE mice [63]. In addition, PPARc and PPARo agonists promote oli-
godendrocyte process extension and cellular maturation [82–84].
Thus, PPARs may require heterodimerization with RXRs to promote
oligodendrocyte maturation and remyelination while also limiting
local inﬂammatory processes.
Finally, many regulators of remyelination are modulated by in-
nate immune mechanisms. TGFß1 as well as lipopolysaccharide, a
TLR4 agonist, promotes upregulation of Jagged1 in astrocytes and
macrophages [31,85,86]. Increased Jagged1 expression leads to
Notch1 activation and further autoampliﬁcation of Notch signaling
[86]. In addition, TLR stimulation can upregulate wnt protein
expression and pathway function [87,88]. Thus, signiﬁcant inter-
play likely exists between remyelinating and inﬂammatory stimuli
in MS lesions.
There is also potential for feedback from remyelination regula-
tors on innate immune activation. RXR stimulation appears to
upregulate TLR4 expression but also inhibits microglial activation
[81,89]. Wnt signaling reduces TNFa production, suggestive of
anti-inﬂammatory effects of the wnt pathway [87]. WntD, a wnt
homolog in Drosophila, acts as a feedback inhibitor of Toll and
the NF-kappaB homologue Dorsal [90]. Hyaluronan and other TLR
agonists have potential to enhance local inﬂammation at least in
the short term [91,92]. However, chronic LPS stimulation (i.e. LPS
tolerance) converts a pro-inﬂammatory signal to a protective func-
tion of macrophages [92]. Therefore, understanding the dynamics
of acute and chronic stimulation of microglia, astrocytes and other
innate immune sensing cells is of critical importance for complete
understanding of remyelination processes in MS.7. Conclusions
In MS pathology studies, two major factors appear to contribute
to impaired remyelination in MS. In MS lesions late in the course of
disease, oligodendrocyte recruitment is deﬁcient and appears to be
the primary reason for poor remyelination in late stage MS. In le-
sions containing more oligodendrocytes, impaired oligodendrocyte
maturation is a major problem with efﬁcient remyelination of le-
sions. While very little work has examined why few oligodendro-
cytes are found within late stage lesions, several mechanism for
blockade of oligodendrocyte maturation have been described,
including Notch1, wnt/ß-catenin, and hyaluronan/TLR2 signaling.
Whether all, some, or none of these possible mechanisms are in-
volved in MS is yet to be established, and this difﬁculty is amply
demonstrated by the recent conﬂicting data on Notch1 and, to
some extent, hyaluronan function in remyelination. Remyelination
and oligodendrocyte maturation also appears to be signiﬁcantly
inﬂuenced by the local inﬂammatory milieu both in ways that pro-
mote and inhibit remyelination. Myelin formed in remyelination
attempts in MS is ultrastructurally abnormal and may also limit
better clinical outcomes. Over the next several years, we anticipate
that a number of these controversies will be resolved and lead to
clinical approaches to enhance remyelination and clinical recovery
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